Status:
UNKNOWN
Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Prostate Cancer
Immune Profile
Eligibility:
MALE
20+ years
Brief Summary
The change of immune profiles and existence of circulating tumor cells following prostate cryotherapy may be correlated with the clinical outcome.
Eligibility Criteria
Inclusion
- Age\>20 years
- Histopathology-proven prostate adenocarcinoma
- Non-metastatic localized disease
- Subjects have chosen their curative, definitive treatments for prostate cancer prior to enrolling for the study
- Subjects are willing to sign the informed consent and agree to comply with the study procedures
Exclusion
- Chronic use (\> 2 weeks) of \> 10 mg/day of prednisone or prednisolone within 2 months of the screening (topical or inhalational corticosteroids are permitted)
- Concurrent use of immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry
- Other conditions the investigators think may affect subjects' compliance
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2015
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01454037
Start Date
October 1 2011
End Date
October 1 2015
Last Update
November 14 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100